Hongming Chen

From Wikipedia, the free encyclopedia

Hongming Chen is an American chemical engineer.

Chen earned a Bachelor's of Science degree in chemical engineering from the University of Texas at Austin in 1992, and completed a Master's and Doctor of Science in the same subject at the Massachusetts Institute of Technology. She then conducted research at Merck & Co. and AstraZeneca. She later helped establish TransForm Pharmaceuticals, which was later acquired by Johnson & Johnson, and subsequently worked for Kala Pharmaceuticals from its founding in 2010, then cofounded Metis Therapeutics.[1]

In 2015, Chen was elected a fellow of the American Institute for Medical and Biological Engineering.[2][3] She was elected to membership of the United States National Academy of Engineering in 2018.[4]

References[edit]

  1. ^ "Five Alumni Honored with Cockrell School Distinguished Graduate Awards for 2021". University of Texas at Austin. 13 September 2022. Retrieved 16 October 2023.
  2. ^ "Hongming Chen, Ph.D. To be Inducted into Medical and Biological Engineering Elite". American Institute for Medical and Biological Engineering. 12 March 2015. Retrieved 16 October 2023.
  3. ^ "HONGMING CHEN, PH.D." American Institute for Medical and Biological Engineering. Retrieved 16 October 2023.
  4. ^ "Dr. Hongming Chen". United States National Academy of Engineering. Retrieved 16 October 2023.